MARKET

ZYNE

ZYNE

Zynerba Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.160
-0.060
-1.42%
After Hours: 4.150 -0.01 -0.24% 17:16 11/23 EST
OPEN
4.250
PREV CLOSE
4.220
HIGH
4.300
LOW
4.100
VOLUME
587.48K
TURNOVER
--
52 WEEK HIGH
7.45
52 WEEK LOW
2.550
MARKET CAP
122.47M
P/E (TTM)
-2.0024
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Zynerba Pharma Reports 2 Posters For Virtual Annual Meeting of the American Epilepsy Society Accepted
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today has announced the acceptance and
Benzinga · 10h ago
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES)
DEVON, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today has announced the acceptance and presentation details of two posters at the 2020 virtual annual meeting of the American Epilepsy Society (AES). The AES annual meeting is being held virtually from December 4th through December 8th, 2020. A copy of the posters will be made available on the Zynerba corporate website at the time of presentation at http://zynerba.com/publications/.   Title: ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Developmental and Epileptic Encephalopathies: An Open‐label Clinical Trial [BELIEVE (ZYN2-CL-25)] Abstract : 913882 Poster : 983 Presentation Date: December 4, 2020Title: Quality of Life and Caregiver Qualitative Assessments in Children with Developmental and Epileptic Encephalopathies Treated with ZYN002 (CBD) Transdermal Gel: BELIEVE (ZYN2-CL-025) Abstract : 913851 Poster : 984 Presentation Date: December 4, 2020About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.  Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.Zynerba Contact Will Roberts, VP Investor Relations and Corporate Communications 484.581.7489 robertsw@zynerba.comMedia contact Molly Devlin Evoke KYNE 215.928.2199 Molly.Devlin@evokegroup.com
GlobeNewswire · 10h ago
The Week In Cannabis: Stocks Down Amid Earnings Season, Argentina Regulates Medical Marijuana
Cannabis stocks were back in the red this week, retreating from post-election highs amid an earnings-heavy period. Over the five trading days of the week:
Benzinga · 11/14 17:49
Earnings Update: Aurora, Canopy Growth, Canopy Rivers And Zynerba Each Post Results
Aurora Posts Q1 EBITDA Loss, Expects Positive EBITDA In Q2
Benzinga · 11/09 16:48
Zynerba Pharmaceuticals Q3 EPS $(0.31) Down From $(0.08) YoY
Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported quarterly losses of $(0.31) per share. This is a 287.5 percent decrease over losses of $(0.08) per share from the same period last year.
Benzinga · 11/09 11:52
Zynerba Pharmaceuticals EPS beats by $0.12
Zynerba Pharmaceuticals (ZYNE): Q3 GAAP EPS of -$0.31 beats by $0.12.Cash and cash equivalents of $64.3M.The company believes that the current cash and cash equivalents is sufficient to fund operations and
Seekingalpha · 11/09 11:51
Canaccord Predicts Over 100% Rally for These 3 Strong Buy Stocks
After passing one speed bump, is the market heading towards more bumps in the road? Following the September sell-off, there has been a surge in COVID-19 cases and limited progress on the next stimulus package. In addition, the likelihood of a Biden victory in the November elections increased.At the same time, however, the broader market has been ramping up, with the NYSE Cumulative Advance/Decline line reaching a record high and the percentage of SPX components trading above their 10-day moving averages landing at 93% for the first time since early April.Weighing in for Canaccord, strategist Tony Dwyer commented, “The strength of the broad market driven by the economy recovery beneficiaries has been dramatic, and while we believe the market should remain volatile (in both directions) into year end, our positive fundamental core thesis driven by excess liquidity and a synchronized global recovery suggests inevitable periods of weakness following these type ramps should be used as an opportunity to add equity exposure.”Turning Dwyer’s outlook into concrete recommendations, Canaccord’s analysts have pinpointed three stocks that could soar in the year ahead, with over 100% upside potential forecasted for each. What’s more, after using TipRanks’ database, we found out that all three have scored enough positive reviews from the broader analyst community to earn a “Strong Buy” consensus rating.Zynerba Pharmaceuticals (ZYNE)Developing next-generation transdermally-delivered cannabinoid therapeutics, Zynerba Pharmaceuticals wants to help improve the lives of patients with rare and near-rare neuropsychiatric conditions. With shares changing hands for $3.65, Canaccord believes that the share price presents an attractive entry point.This summer, ZYNE revealed that in the CONNECT-FX pivotal trial evaluating Zygel, its transdermal cannabidiol gel, in Fragile X syndrome (FXS), the therapy did not achieve statistical significance on its primary or secondary endpoints in the full analysis set, or 210 patients. That being said, it did demonstrate significance on the primary endpoint in patients with full methylation of the FMR1 gene, which was an ad-hoc pre-planned analysis, and secondary endpoints were promising.Of the patients in the trial, 80% had full methylation, and the company estimates 60% of the 71,000 U.S. FXS patients fall into this category. To this end, ZYNE will meet with the FDA to discuss the next steps for potential approval in this indication, likely in 2H20.Writing for Canaccord, 5-star analyst Sumant Kulkarni believes that “the key to ZYNE stock lies in the outcome of the company's interactions with the FDA on its clinical programs for Zygel... It is always difficult to second-guess what the agency might do, but a ‘good’ outcome would involve ZYNE being potentially able to file Zygel for approval in fully-methylated FXS patients. Given there are no products approved for FXS, such an outcome, with perhaps a confirmatory trial to be run, cannot be ruled out.”Given this result, Kulkarni argues ZYNE will now target the fully-methylated FXS patients. With the analyst seeing the targeting of this subgroup as “the best way forward for its FXS program,” he continues to model a 50% probability of approval for Zygel in FXS.Additionally, ZYNE is expected to report results from its discussions with the FDA on the path forward for Zygel in developmental and epileptic encephalopathies (DEE) in Q3 2020, and meet with the FDA on its program in autism spectrum disorder (ASD) in 2H20. Therefore, “there could be opportunity for risk-tolerant investors ahead of news on the outcome of FDA interactions,” in Kulkarni’s opinion.With new posters released yesterday, supporting Zygel in Fragile X and Autism, Kulkarni stays with the bulls. To this end, the top analyst rates ZYNE a Buy along with a $12 price target. Investors could be pocketing a gain of 215%, should this target be met. (To watch Kulkarni’s track record, click here)Turning to the rest of the Street, the bulls have it on this one. With 3 Buys and a lone Hold, the word on the Street is that ZYNE is a Strong Buy. At $13, the average price target implies 245% upside potential. (See ZYNE stock analysis on TipRanks)Atreca (BCEL)Bringing a deep understanding of the human immune response to the table, Atreca develops innovative immunotherapies. Ahead of a key data readout, Canaccord is pounding the table on this healthcare play.Representing the firm, 5-star analyst John Newman has high hopes for ATRC-101, its product that targets a differentiated intracellular protein, PolyAdenylate Binding Protein (PABP-1) which is restricted to tumor tissues.According to the analyst, this suggests ATRC-101 “will have a favorable safety profile and will not affect healthy tissues.” He added, “Importantly, ATRC-101 can be clinically impactful in a number of tumor types including: lung, breast, ovarian, colon, skin, and liver cancers, which comprise a large market opportunity.”Further speaking to the candidate’s potential, ATRC-101's cutting-edge mechanism of action (MOA) involves both innate response through binding of tumor tissues, and adaptive response via delivering tumor associated antigens to macrophages and dendritic cells. The dendritic cells are then stimulated, releasing chemokines, cytokines and promoting a CD8+ T-cell response, which kills tumor cells. The company has already published data to support the MOA, which is helpful to better “understand the underpinnings of the drug's efficacy,” in Newman’s opinion.As screening is underway in the ATRC-101 monotherapy study, and patients are currently being enrolled in the second cohort dose, Newman expects initial safety data to come by YE20 and early 2021, respectively. “With the second cohort dose starting and first cohort dose showing promising preclinical results, we look forward to progression of the cohort doses and eventually initiating the third cohort dose,” he noted.On top of this, Newman is optimistic about the trial evaluating ATRC-101 in combination with PD-1 inhibitor and chemotherapeutic agents, which is slated to kick off in 2021. “Chemotherapy has shown to induce the target of ATRC-101, which could lead to positive outcomes. Chemotherapy can also increase ATRC-101's target expression, promote antigen release, and can allow earlier use of ATRC-101 in treatment paradigms,” he explained.Everything that BCEL has going for it convinced Newman to reiterate his Buy rating. In addition to the call, he left the price target at $33, suggesting 120% upside potential. (To watch Newman’s track record, click here)All in all, other analysts are on the same page. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. With an average price target of $28.67, the upside potential comes in at 91%. (See BCEL stock analysis on TipRanks)Cara Therapeutics (CARA)Hoping to provide solutions for those suffering from chronic pruritus, Cara Therapeutics develops peripherally acting kappa opioid agonist therapeutics. Following an update on the company’s development candidates, Canaccord sees a compelling opportunity.Firm analyst Arlinda Lee tells clients that she recently spoke with CARA President and CEO Dr. Derek Chalmers, and he provided upbeat commentary on lead candidate Korsuva, a kappa opioid receptor agonist designed for moderate to severe pruritus.One of the analyst’s key takeaways was that oral Korsuva has the potential for a broad label in chronic atopic dermatitis (AD - eczema or itchy skin). AD affects roughly 20 million people in the U.S., and it is a complex disease, with the mechanisms of pruritus still being studied. Dr. Chalmers argues that Korsuva's MOA is agnostic to the type and level of cytokine release in the skin as kappa opioid receptor agonists work downstream of cytokine interaction, and cytokine release is also inhibited.It should be noted that regardless of pathology, the incidence of pruritus in AD is 100%, with approximately 20% classified as moderate to severe. For the 80% of patients with mild to moderate itch, biologics and immunosuppressants are not appropriate. “With its benign safety profile, oral Korsuva may be well-positioned to serve this patient segment with a frontline systemic treatment,” Lee commented. Therefore, she believes the release of Phase 2 oral Korsuva AD data in 2021 could drive serious upside.In the Phase 2 trial evaluating oral Korsuva for chronic kidney disease associated pruritus (CKD-aP) in non-hemodialysis patients, there was a 50% placebo response, but two factors could have caused this. Earlier stage CKD patients have intermittent pruritus, so they are more susceptible to placebo response. Additionally, CARA used sites and investigators that had experience with IV Korsuva and expectation bias may have been transferred to non-hemodialysis patients, according to Dr. Chalmers. “CARA can mitigate these by utilizing a longer run-in period for more consistent patients; using de novo sites to eliminate expectation bias; and employing 1:1 randomization,” Lee mentioned.If that wasn’t enough, the IV Korsuva NDA filing for CKD-aP is expected in Q4 2020. Lee thinks the chances of an FDA AdCom are low, based on its robust safety profile and number of New Chemical Entities recently approved without an AdCom. IV Korsuva might not be classified as a scheduled controlled substance, given that it lacks traditional opioid side effects and acts in the periphery, not the central nervous system (CNS).Taking the above into consideration, Lee maintains a Buy rating and $30 price target. This target conveys her confidence in CARA’s ability to climb 124% higher in the next year. (To watch Lee’s track record, click here)Are other analysts in agreement? They are. Only Buy ratings have been issued in the last three months. Therefore, the consensus is unanimous: CARA is a Strong Buy. Given the $32.67 average price target, shares could climb 118.5% in the next year. (See Cara stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
TipRanks · 10/16 16:01
Zynerba Up 6% As Zygel Shows Promise In Autism Trial
Shares in Zynerba Pharma (ZYNE) jumped 6.4% in Thursday’s trading, and continued to climb 1.6% after-hours, after new data from the Phase 2 Bright trial showed the potential for Zygel (ZYN002) to improve behavioral symptoms of autism alongside stable standard of care in children and adolescents with moderate-to-severe autism spectrum disorder (ASD).“The Phase 2 BRIGHT trial provides the first clinical evidence of the potential for Zygel to improve behavioral symptomology in a group of highly symptomatic pediatric and adolescent patients with ASD,” said Helen Heussler, principal investigator in the trial.“In these children receiving Zygel, the observed changes from baseline are promising. In particular, the improvements seen in core symptoms of autism, as specifically assessed by the Autism Impact Measure, are of special interest” she added.The BRIGHT Phase 2 trial is an exploratory, single-center, open-label Phase 2 study evaluating the safety and tolerability and efficacy of Zygel in children and adolescents with ASD who are 3 to <18 years old.New data presented revealed that patients receiving Zygel achieved statistically significant caregiver-reported improvements compared to baseline across the core ASD symptoms, namely: Atypical behavior, Communication, Peer Interaction, Repetitive Behavior, and Social Reciprocity.In addition, statistically significant improvements compared to baseline were observed at week 14 of treatment with Zygel in the Autism Parenting Stress Index.Zynerba also measured notable improvements in behaviors utilizing the Qualitative Caregiver Behavioral Problems Survey after 14 weeks of study drug. Clinically meaningful improvements were observed by a majority of surveyed caregivers in behavioral, social and emotional behavioral problems.Zygel was also very well tolerated and the safety profile was consistent with previously released data from other Zygel clinical trials. No serious or severe adverse events were reported.Zynerba focuses on pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders including Fragile X syndrome and developmental and epileptic encephalopathies. (See ZYNE stock analysis on TipRanks)Shares in the company have plunged 37% year-to-date, but the stock scores a bullish Strong Buy Street consensus with 3 recent buy ratings vs 1 hold rating. Meanwhile the average analyst price target stands at $13 (242% upside potential).“We continue to believe ZYNE is offering investors a compelling entry point this fall when paired against its peers: including Zogenix and Stoke” comments Ladenburg Thalmann analyst Michael Higgins. He has a buy rating on the stock and $15 price target.Related News: Vertex Sinks 12% On Halt of VX-814 Development; Merrill Lynch Says Buy J&J Halts Covid-19 Vaccine Trial Due To ‘Unexplained Illness’ Amarin Pops 4% After-Hours On Positive PCI Data For Vascepa More recent articles from Smarter Analyst: * Intuitive Surgical Plunges 4% Despite 3Q Earnings Beat * Cars.com Soars 26% On Strong 3Q Sales Outlook, Analyst Upgrade * Zogenix Rallies 7% On New Fintepla Data For Dravet Syndrome * Marten Transport Sinks 8% After-Hours On 3Q Revenue Miss
SmarterAnalyst · 10/16 07:55
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZYNE. Analyze the recent business situations of Zynerba Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZYNE stock price target is 10.00 with a high estimate of 15.00 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 132
Institutional Holdings: 5.63M
% Owned: 19.13%
Shares Outstanding: 29.44M
TypeInstitutionsShares
Increased
13
190.12K
New
33
-1.10M
Decreased
29
1.24M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Chief Executive Officer/Director
Armando Anido
President
Terri Sebree
Chief Financial Officer/Vice President
James Fickenscher
Vice President/General Counsel/Secretary
Suzanne Hanlon
Vice President/Director of Investor Relations
William Roberts
Vice President
Brian Rosenberger
Lead Director/Independent Director
Warren Cooper
Independent Director
John Butler
Independent Director
William Federici
Other
Liza Squires
Independent Director
Daniel Kisner
Independent Director
Kenneth Moch
Independent Director
Pamela Stephenson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ZYNE
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Zynerba Pharmaceuticals Inc stock information, including NASDAQ:ZYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZYNE stock methods without spending real money on the virtual paper trading platform.